David Becker is a partner in the Firm's Capital Markets, High Yield & Leveraged Finance Group. David joined the Firm in 2019 after having spent a total of 20 years in the Wall Street and London offices of two other leading international law firms.
David is a highly regarded high yield and leveraged finance specialist, advising banks, private credit and alternative capital providers, borrowers and issuers on a broad range of high yield, leveraged finance, liability management and restructuring transactions across the debt capital structure and over the full credit life cycle.
Representative Legal Matters
- Acting for the initial purchasers on the US$2.1 billion (equivalent) dual-tranche high yield bond offering by certain subsidiaries of Teva Pharmaceutical Industries Limited, comprised of a US$1 billion 7.125% five-year tranche and a EUR 1 billion 6.000% five-year tranche. Advised the dealer managers on the concurrent 3 tiered priority-acceptance tender offer to purchase up to US$1.5 billion of certain of its other outstanding bonds.
- Acting for the initial purchasers in connection with the issuance by Cabot Financial (Luxembourg) II S.A. of EUR 400 million aggregate principal amount of senior secured floating rate notes due 2024.
- Acting for the lenders with respect to a USD 2.3 billion credit facility for Teva Pharmaceutical Industries Limited and certain of its subsidiaries.
- Represented the lead arrangers, Bank of America Merrill Lynch, Barclays, BNP Paribas, Citi, Credit Suisse, HSBC, Mizuho Bank, Morgan Stanley, RBC and Sumitomo Mitsui, in their USD 33.75 billion acquisition financing commitments to Teva Pharmaceutical Industries Ltd. to fund Teva's US$40.5 billion acquisition of Allergan Generics and subsequent related liability management transactions.
- David has also represented the lending banks for the committed financing for Teva's unsolicited approach to Mylan, Teva's acquisition of Cephalon, Teva's acquisition of Ratiopharm and Teva's acquisition of Taiyo Pharmaceuticals, for a total of approximately USD 66 billion of committed acquisition and corporate financing to Teva since 2009.
- Represented LabTech Group in its GBP 900 million senior secured financing facility with AIG.
- Represented GSO Capital Partners in the EUR 600 million private high yield to fund the merger of Polynt Composites and Reichhold.
- Represented CEE Equity Partners on the first lien / second lien financing for its acquisition of Hungarian telcom Invitel.
- Represented Stifel Nicolaus and the other initial purchasers on the USD 325 million senior high yield bond offering and recapitalisation for 4finance and the related tender and exchange offer
- Represented Bank of America Merrill Lynch as mandated lead arranger in the EUR 350 million refinancing for Ülker Bisküvi.
- Represented GSO Capital Partners and other co-investors in approximately USD 1 billion in committed financing across Amaya's capital structure to finance Amaya's USD 4.9 billion acquisition of online poker giant Rational Group (owner of the Pokerstars and Fulltilt brands), creating the world's largest publically traded i-gaming company.
- David represented Barclays and JPMorgan in USD 600 million of senior secured financing commitments to back 888 Holding’s recommended bid for Bwin.party.
- England & Wales (Registered Foreign Lawyer) (2019)
- New York~United States (1999)
- Columbia University School of Law (JD)
- Yeshiva University (BA)
Baker & McKenzie LLP, an English partnership, is a member of Baker & McKenzie International, a Swiss Verein.